EGFR and non-small cell lung carcinoma: The PI3K/Akt and MAPK signaling pathways are widely reported to participate in the regulation of PD-L1 in many tumours, and NF-kappa B was found to be involved in the EGFR-TKI induced downregulation of PD-L1 in EGFR-mutant NSCLC [38].